Contribution of Oxidative Stress in Asthma Exacerbated Respiratory Disease (AERD) Through Measurement of 8-isoprostane F2-alpha

Overview

About this study

The purpose of this study is to determine the contribution of oxidative stress as an underlying cause in asthma exacerbated respiratory disease (AERD) through the measurement of urine 8-isoprostane F2-alpha.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Case Group:

  • Patients will be recruited for inclusion into the study through the Division of Allergic Diseases at Mayo clinic, Rochester, MN.
  • Patients with aspirin exacerbated respiratory disease (AERD) as identified through clinical history and/or prior positive aspirin intolerance and scheduled to undergo an aspirin challenge and desensitization in the allergic diseases clinical laboratory (L15)
    • Aspirin desensitization is considered standard care for AERD patients and there would not be any deviation from the usual process. Written informed consent will be obtained prior to starting the procedure of desensitization.
  • Only those patients agreeing to participate in the study will be included.

Control Group:

  • Identified by providers in Allergy Clinic as those who have asthma and are aspirin tolerant (ATA, aspirin tolerant asthmatics)
  • Diagnosis of asthma will be defined either as
    • Physician assigned diagnosis of asthma based on the clinical judgment or 
    • Presence of episodic symptoms of breathlessness, chest tightness, wheezing, cough or phlegm production (one or more) PLUS spirometric data supporting diagnosis of asthma

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Rohit Divekar, M.B.B.S., Ph.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions